Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: attention placebo Clear all
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 5, 2026, 6:23 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alcohol Inhibits Drug Metabolism by Carboxylesterases

NCT01708369
View directory record Official record
Conditions
Drug Interactions
Interventions
Placebo, Ethanol, Oseltamivir, Aspirin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 5, 2026, 6:23 AM EDT
Withdrawn Phase 3 Interventional

A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators

NCT00458445
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPD465, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 5, 2026, 6:23 AM EDT
Recruiting Phase 3 Interventional

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03016819
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions
AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 4 Interventional

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

NCT00299234
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 2 Interventional

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

NCT05948592
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
TP-102, Placebo
Biological · Other
Lead sponsor
Technophage, SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

NCT05104853
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
CNP-104, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Coronado, California • Lancaster, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

Neuroimaging of the Effects of Concerta in the Treatment of ADHD

NCT00778310
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate-OROS, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
9 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 5, 2026, 6:23 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

NCT01920477
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Ofatumumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goals for Reaching Optimal Wellness: GROWell

NCT04449432
View directory record Official record
Conditions
Pregnancy Related, Gestational Weight Gain, Postpartum Weight Retention, Overweight and Obesity
Interventions
GROWell (Interactive Obesity Treatment Approach), Attention Support Control
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

NCT03265119
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 4 Interventional Results available

Effect of Valproic Acid Concentration on Photic Response

NCT00609245
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
15 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chesterfield, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Not applicable Interventional Results available

Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)

NCT00868140
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

NCT00482989
View directory record Official record
Conditions
Lupus
Interventions
MEDI 545, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

NCT00158743
View directory record Official record
Conditions
Pre-eclampsia
Interventions
Anti-digoxin antibody (FAB fragment), sodium chloride
Drug · Other
Lead sponsor
BTG International Inc.
Other
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886
View directory record Official record
Conditions
Back Pain
Interventions
cognitive behavioral therapy, desipramine hydrochloride, benztropine mesylate 0.125 mg daily
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 5, 2026, 6:23 AM EDT
Completed Phase 3 Interventional

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

NCT00301236
View directory record Official record
Conditions
ADHD, ADD
Interventions
Dexmethylphenidate HCl extended-release capsules
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
252 participants
Timeline
2006
U.S. locations
25
States / cities
Mesa, Arizona • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 5, 2026, 6:23 AM EDT
Terminated Phase 4 Interventional Results available

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

NCT02549716
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Stroke
Interventions
IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 5, 2026, 6:23 AM EDT